| Cancer Treatment and Pharmacology | Lifetime | 21 | US 12 | 99.90 |
| Cancer therapeutics and mechanisms | Lifetime | 23 | US 16 | 99.72 |
| Colorectal Cancer Treatments and Studies | Lifetime | 48 | US 22 | 99.75 |
| HER2/EGFR in Cancer Research | Lifetime | 35 | US 18 | 99.79 |
| Lung Cancer Treatments and Mutations | Lifetime | 77 | US 46 | 99.75 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 28 | US 17 | 99.67 |
| Peptidase Inhibition and Analysis | Lifetime | 77 | US 39 | 99.61 |
| Advanced Breast Cancer Therapies | Lifetime | 28 | US 12 | 99.65 |
| Lung Cancer Research Studies | Lifetime | 102 | US 57 | 99.50 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 251 | US 159 | 99.47 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 229 | US 118 | 99.29 |
| Neutropenia and Cancer Infections | Lifetime | 70 | US 37 | 99.14 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 406 | US 215 | 99.06 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 340 | US 170 | 99.02 |
| Chemotherapy-related skin toxicity | Lifetime | 41 | US 24 | 98.10 |
| Cancer Diagnosis and Treatment | Lifetime | 437 | US 220 | 97.82 |
| CAR-T cell therapy research | Lifetime | 655 | US 388 | 98.21 |
| Cancer Genomics and Diagnostics | Lifetime | 987 | US 502 | 98.28 |
| Cancer-related Molecular Pathways | Lifetime | 660 | US 354 | 97.78 |
| Neuroendocrine Tumor Research Advances | Lifetime | 750 | US 297 | 97.64 |
| Breast Cancer Treatment Studies | Lifetime | 754 | US 337 | 97.85 |
| PARP inhibition in cancer therapy | Lifetime | 272 | US 136 | 96.45 |
| Cancer Research and Treatments | Lifetime | 887 | US 462 | 96.08 |
| Cancer Mechanisms and Therapy | Lifetime | 463 | US 201 | 95.45 |
| Melanoma and MAPK Pathways | Lifetime | 371 | US 198 | 96.28 |
| Multiple Myeloma Research and Treatments | Lifetime | 784 | US 350 | 96.28 |
| Histone Deacetylase Inhibitors Research | Lifetime | 771 | US 353 | 93.84 |
| Protein Degradation and Inhibitors | Lifetime | 883 | US 426 | 94.38 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 217 | US 46 | 95.89 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 998 | US 357 | 96.20 |
| Advanced Breast Cancer Therapies | 2021-2025 | 204 | US 77 | 96.36 |
| Peptidase Inhibition and Analysis | 2021-2025 | 318 | US 93 | 93.64 |
| Cancer-related Molecular Pathways | 2021-2025 | 239 | US 98 | 88.91 |
| Cancer Diagnosis and Treatment | 2021-2025 | 417 | US 103 | 83.10 |
| HER2/EGFR in Cancer Research | 2021-2025 | 808 | US 265 | 87.23 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 385 | US 135 | 74.17 |
